Loading
A phase 2 trial of Epcoritamab in diffuse large b-cell lymphoma and follicular lymphoma, run by Genmab, active and no longer recruiting.
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma is a phase 2 interventional study registered as NCT05451810 by Genmab, with 184 participants planned, started 2022-08-17 and due to reach its primary completion in 2027-03. Interventions recorded: Epcoritamab. Conditions listed: Diffuse Large B-Cell Lymphoma, Classic Follicular Lymphoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Epcoritamab, Genmab, T-cell engagers (bispecific), Diffuse large B-cell lymphoma.
Shares Epcoritamab, Genmab, T-cell engagers (bispecific), Diffuse large B-cell lymphoma.
Shares Epcoritamab, Genmab, T-cell engagers (bispecific), Follicular lymphoma.
Shares Epcoritamab, Genmab, T-cell engagers (bispecific), Follicular lymphoma.
Shares Epcoritamab, Genmab, T-cell engagers (bispecific), Follicular lymphoma.
Shares Epcoritamab, Genmab, T-cell engagers (bispecific), Diffuse large B-cell lymphoma.
Shares Epcoritamab, Genmab, T-cell engagers (bispecific), Diffuse large B-cell lymphoma.
Shares Epcoritamab, Genmab, T-cell engagers (bispecific).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/